ArticleJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society2015
Effect of diabetes mellitus on giant cell arteritis.
Article in Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 35 citations in OpenAlex.
- Causal association of type 2 diabetes with central retinal artery occlusion: a Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis: A Population-Based Study.The Journal of rheumatology · 2023Article
- Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis.Rheumatology (Oxford, England) · 2020Article
- The relationship between glycated haemoglobin levels and the risk of giant cell arteritis - a case-control study.Rheumatology advances in practice · 2020Article
- Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- Ophthalmic presentation of giant cell arteritis in African-Americans.Eye (London, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTo determine if Type 2 diabetes mellitus (DM) is protective against giant cell arteritis (GCA) and to estimate the incidence of GCA diagnosis from Medicare claims.
methodsMedicare 5% claims files from 1991 to 2011 were used to identify beneficiaries diagnosed with DM, but not GCA, within a 3-year ascertainment period. Propensity score matching was used to define a control group of nondiabetics with comparable demographic covariates. Competing risk regression was then used to assess the impact of DM diagnosis on GCA diagnosis. To allow for a 3-year ascertainment period, the analysis sample was limited to beneficiaries older than 68 years at baseline.
resultsA total of 151,041 beneficiaries diagnosed with DM were matched to an equal number of controls. Mean study follow-up was 67.75 months. GCA was diagnosed among 1116 beneficiaries with DM (0.73%) vs 465 (0.30%) controls. The risk of receiving a GCA diagnosis among patients with DM was increased by 100% (subhazard ratio, 2.00; 95% confidence interval, 1.78-2.25). The annual incidence of GCA diagnosis among claims for US Medicare beneficiaries older than 68 years old was 93 in 100,000.
conclusionsA DM diagnosis is not protective against a GCA diagnosis in the Medicare population. Our data suggest that a DM diagnosis increases the risk of GCA diagnosis within 5.7 years for Medicare beneficiaries older than 68 years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.